Navigation Links
Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products
Date:5/31/2011

RALEIGH, N.C., May 31, 2011 /PRNewswire/ -- Today, Campbell Alliance released the results of its Oncology National Commercial (ONC) Study, the latest in its Landmark Study series.  A summary report of the study's findings is available at www.campbellalliance.com, and the firm is sharing a more in-depth presentation of the results with its clients by request.

The ONC Study explores the factors that have caused major changes in the oncology market over the past 10 years and evaluates how those factors will continue to shape the market during the next decade.  It also provides recommendations on how pharmaceutical and biotech companies should manage the increasingly challenging oncology market environment.

To gather information for the study, Campbell Alliance interviewed decision makers from 9 of the world's top-20 pharmaceutical and biotech companies, a range of national and regional payer organizations, and several integrated delivery systems, as well as 10 oncology key opinion leaders and 20 community hematologists/oncologists.

According to Jeff Stewart, one of the study's authors, "We felt it was the right time to document how much oncology has changed over the past decade and take a look forward.  In truth, the extent of change has been breathtaking.  New therapies are only the beginning of the story.  Oncologists have changed.  Payers have changed.  Sales forces have changed.  Medicare has changed.  Financial incentives have changed, and patients have changed.  It's a different world, and it continues to evolve."

The study outlined 10 key trends that will shape the market for years to come.  Five of the trends relate to product development, while the other five relate to commercial issues.  The study's report indicates that these trends—when their effects are combined—are bringing about a "perfect storm" in oncology that will make the environment far more challenging for pharmaceutical and biotech firms.  According to the report's authors, the study's objective is to help industry decision makers understand the drivers of change within their environment and begin developing strategies that will help their companies thrive in a market that will only get more challenging over the next few years.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms.  Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan.

For Campbell Alliance:
James Forte
Campbell Alliance
919-844-7100 ext. 7195
jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Beardsworth Continues to Strengthen Oncology Operations
4. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
5. Caliper Announces New Oncology Research Collaboration
6. Champions Biotechnology Changes Name to Champions Oncology
7. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
8. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
9. D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
10. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
11. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):